ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Torsemide

Also written as “Torasemide tablet 10 mg”, “torasemide” and “torsemide”.

Its studies are mostly in Heart Failure · Edema · Body Weight Changes · Hypertension · Diabetes Mellitus, Type 2, led by 5 companies.

Drug pageTorsemide: every studyMany companies study it; this page follows only the 11 they lead. All 23 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 24, 202411 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sarfez Pharmaceuticals40 open or runningphase 4since Nov 24, 2024Apr 17, 2018none ahead
Ferrer Internacionalits history only20 open or runningphase 4since Jun 6, 2006Jun 6, 2006none ahead
Hikma Pharmaceuticalsits history only20 open or runningno phasesince Jan 15, 2008Jan 15, 2008none ahead
Par Healthits history only20 open or runningphase 1since Apr 1, 2008Apr 1, 2008none ahead
Menarini Groupits history only11 open or runningphase 1since Sep 10, 2025Sep 10, 2025none ahead

Also a collaborator on its studies: Anapharm.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sarfez Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 17, 2018First study: phase 1 study in Body Weight ChangesFirst studyNCT03509545 · 20 enrolled · India
  2. Nov 24, 2024Phase 4 study in Heart FailureNCT06708611 · United States
  3. Jun 3, 20252 phase 3 studiesNCT07015671, NCT07046975

TargetBeta

SLC12A1 →read by rule
“Sodium-(potassium)-chloride cotransporter 2 inhibitor”ChEMBL 37, by rule

Other programs on SLC12A1

ProgramCompanyFurthest phaseStudies
FurosemideruleBoehringer Ingelheimphase 427

Studies

All 4 Sarfez Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07046975Bioavailability Heathy Volunteers · United States3CompletedFeb 28, 202624
NCT07015671Bioequivalence Study in Healthy Subjects · United States3CompletedDec 30, 202524
NCT06708611Heart Failure · United States4WithdrawnMar 25, 20250
NCT03509545Body Weight Changes · India1TerminatedJun 30, 202220

How it is read

Names in the registry

  • “Torsemide”, 4 entries
  • “Torasemide tablet 10 mg”, 2 entries
  • “torasemide”, 2 entries
  • “torsemide”, 1 entry
  • “CHF Patients: ER Torsemide 40 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.